Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline include... Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN). 詳細を表示
Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders Announced the expansion of patent...
Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales Enveric Biosciences, Inc. (NASDAQ:...
New patents expand the number and type of compounds available for development and the possible indications targeted, increasing the potential value of Enveric’s drug candidate library Enveric...
In vitro pharmacology studies confirmed EB-003’s ability to target desired serotonergic receptors, supporting the potential of the neuroplastogenic therapeutic candidate to address...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.070401 | -17.5958070587 | 0.400101 | 0.4363 | 0.3051 | 186085 | 0.36884414 | CS |
4 | -0.2178 | -39.7808219178 | 0.5475 | 0.55 | 0.3051 | 272872 | 0.44715967 | CS |
12 | -0.1971 | -37.4145785877 | 0.5268 | 0.56 | 0.3051 | 543391 | 0.4425818 | CS |
26 | -0.5093 | -60.7032181168 | 0.839 | 0.85 | 0.3051 | 811543 | 0.52980076 | CS |
52 | -1.1303 | -77.4178082192 | 1.46 | 2.92 | 0.3051 | 1610979 | 1.12571128 | CS |
156 | -1.3203 | -80.0181818182 | 1.65 | 14.87 | 0.1551 | 1389732 | 1.66625881 | CS |
260 | -5.4703 | -94.3155172414 | 5.8 | 14.87 | 0.1551 | 1892764 | 2.46931905 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約